Epitaxial HAP Coating on CAP Core for Bone Substitute Stability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing calcium phosphate/hydroxyapatite (CAP/HAP) bone substitute materials face accelerated degradation in vivo due to differences in solubility between CAP and HAP, leading to local calcium ion oversaturation and increased osteoclast activity, potentially causing adverse inflammation reactions.
Innovation Solution
A biphasic CAP/HAP bone substitute material with a sintered CAP core and a uniform, epitactically grown layer of nanocrystalline HAP, where the epitactically grown layer has a non-homogeneous external surface with individual clusters of flat crystal platelets and coarse areas, enhancing osteostimulation and controlled calcium release.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If CAP/HAP systems are implanted into a mammal, then the material provides bone substitute function, but the solubility difference between TCP and HAP causes accelerated degradation and local calcium ion oversaturation
Solution Approach 1:
The patent changes the chemical composition parameters of the bone substitute material by using stoichiometric hydroxyapatite (HA) with precise Ca:P ratio of 1.67, eliminating the soluble TCP component that causes accelerated degradation. This parameter optimization resolves the contradiction by maintaining material stability while preventing calcium ion oversaturation.
Solution Approach 2:
The patent creates a composite structure combining sintered calcium phosphate core with epitaxially grown hydroxyapatite coating, where the HA coating protects the core and provides controlled degradation. This composite approach maintains reliability while controlling the degradation timeline to prevent adverse reactions.
2Strength
If sintered CAP core material is used, then the material provides structural support, but the sintered interconnection increases solubility and accelerates degradation
Solution Approach 1:
The patent introduces hydroxyapatite coating as an intermediary layer between the sintered CAP core and the physiological environment. This HA coating acts as a protective barrier that reduces the solubility of the underlying CAP material, thereby preventing accelerated degradation while maintaining structural support functionality.
Solution Approach 2:
The patent utilizes the porous structure of sintered calcium phosphate material to provide structural support and osteoconductivity, while controlling the pore architecture to balance mechanical strength with controlled degradation rates, preventing excessive material loss.
3Productivity
If local calcium equilibrium is disturbed by CAP dissolution, then osteoclast activity increases, but this leads to accelerated resorption and inflammation risk
Solution Approach 1:
The patent optimizes the chemical composition to use stoichiometric hydroxyapatite with precise Ca:P ratio of 1.67 and controlled carbonate content (CO3 2- ions replacing PO4 3- ions), which maintains local calcium equilibrium by providing controlled, sustained calcium release rather than sudden oversaturation, thereby preventing inflammation while stimulating bone formation.
Solution Approach 2:
The patent converts the natural solubility of calcium phosphate materials from a harmful factor (causing calcium oversaturation and inflammation) into a beneficial controlled-release mechanism. By carefully controlling the degradation rate through composition optimization, the material provides sustained calcium supply that promotes bone formation without triggering adverse inflammatory responses.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The material promotes increased bone formation by maintaining a stable calcium equilibrium, reducing osteoclast activity, and minimizing inflammation risks, as demonstrated by enhanced bone area density in rabbit models.
Implementation Method 1
a uniform and closed epitactically grown layer of nanocrystalline HAP is formed on the external surface of the sintered CAP core
Implementation Method 2
Chemical dissolution and biological resorption by cells. Both processes cause dissolution of the ceramic material
Data Source
Figure 1A~1B
Figure 2A~2B
Figure 3
AI summary
A biphasic calcium phosphate/hydroxyapatite (CAP/HAP) bone substitute material having a sintered CAP core and at least one closed epitactically grown layer of nanocrystalline HAP deposited on the external surface of the sintered CAP core, whereby the epitactically grown nanocrystals have the same size and morphology as human bone mineral, wherein the closed epitactically grown layer of nanocrystalline HAP deposited on the external surface of the sintered CAP core has a non-homogeneous external surface comprising individual clusters of flat crystal platelets consisting of epitactically grown HAP nanocrystals and coarse areas between the individual clusters, whereby the percentage of the coarse areas between the individual clusters as measured by SEM is at least 20% of the total surface, which material shows an increased capacity to induce bone formation, and a process of preparation thereof.